April 8, 2024 4:50pm

A slow walk to a closing with divided views of share pricing, Fed speakers, growing clatter about the coming US presidential election, and a spike in oil prices and treasury yields

The Harvard Apparatus RT (OTCQB HRGN) formerly Biostage (BSTG) Chronicles: Question, Is it a Ponzi Scheme? How much lipstick is a lot on this pig; the facts outweigh their future and circumstance to raise capital, they have burned too many bridges!<see The Bottom Line>

Pre-open Indications: 3 Hits and 1 Miss

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading!  A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio defense.

Never leave an investor uninformed! A trusted source of factual reporting!

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence! 

 

Monday: The Dow closed DOWN -11.24 points or -0.03%, the S&P closed DOWN -1.95 points or -0.04% while the Nasdaq closed UP +5.43 points or +0.03%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes were mixed Monday as investors tried to regain their footing following a pullback last week.

“The theme of bad news being good for the equity market continues,” said Matt Rowe, head of portfolio management at Nomura Capital Management. “Much of the equity strength is driven off of hope for an implied cut, or a series of rate cuts this year, that won’t take down the cost of capital and present value of everything.” <CNBC>

 

Monday’s RegMed Investors’ (RMi) opening bell: “expectation versus circumstances. There’s also a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules.” … https://www.regmedinvestors.com/articles/13407

 

Advance/Decline (A/D) Line:

  • Monday’s advance/decline line at the open was negative with 8 incliner, 26 decliners and 1 flat; ending with a positive close of 23 incliners, 12 decliners and 0 flat

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q2/24: 5 negative and 1 positive closes

Q1/24:

  • March, 1 holiday, 8 positive and 12 negative closes
  • February, 1 holiday, 9 negative and 11 positive closes
  • January: 2 holiday, 12 negative and 8 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was up +0.24% and the XBI was up +0.24%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -0.84 point or -5.24% at 15.19

 

Monday’s Closing Down (10 of 12):

  • Ionis Pharmaceuticals (IONS -$0.98 after Friday’s +$0.39),
  • Vericel (VCEL -$0.84 after Friday’s +$0.65),
  • Voyager Therapeutics (VYGR -$0.27 after Friday’s +$0.20),
  • Solid Biosciences (SLDB -$0.26 after Friday’s -$0.22),
  • Fate Therapeutics (FATE -$0.21),
  • Caribou Biosciences (CRBU -$0.14),
  • Verve Therapeutics (VERV -$0.12 after Friday’s -$0.16),
  • Blueprint Medicine (BPMC -$0.11 after Friday’s +$0.97),
  • MiMedx (MDXG -$0.10),
  • Graphite Bio (GRPH -$0.09 after Friday’s -$0.09),

Monday’s Closing Up (10 of 23):

  • Alnylam Pharmaceuticals (ALNY +$2.48 after Friday’s +$2.08),
  • CRISPR Therapeutics (CRSP +$1.19 after Friday’s -$2.16),
  • Beam Therapeutics (BEAM +$0.61 after Friday’s -$0.83),
  • Intellia Therapeutics (NTLA +$0.52 after Friday’s -$0.19),
  • Mesoblast (MESO +$0.49 after Friday’s -$0.09),
  • Harvard Apparatus RT (HRGN+$0.48 after Friday’s $0.00),
  • Generation Bio (GBIO +$0,39).
  • Prime Medicine (PRME +$0.35),
  • Sage Therapeutics (SAGE +$0.18 after Friday’s -$0.16),
  • BioLife Solutions (BLFS +$0.18),

 

Q2/24 – April

  • (4/8) Monday closed positive with 23 incliners, 12 decliners and 0 flat
  • Friday closed negative with 10 incliners, 23 decliners and 2 flats

 

The BOTTOM LINE: Indexes wobbled on Monday yet did close POSITIVE as investors kicked off a big week that will see a fresh inflation data test for rate-cut views and the start Q1 earnings season.

  • Cell and gene therapy sector equities closed positive after a negative open on Monday following the week’s 5 session decline, after the jobs report followed by Thursday, Wednesday, Tuesday and Monday
  • Last week, I wrote that I favor … caution over the next few weeks!

 

“I ALSO reiterate, “Don't chase the cell and gene therapy sector, especially with the Nasdaq extended.” Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

 

The top three (3) performing in the session:

  • Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)

The worst three (3) in the session:  

  • Monday: Ionis Pharmaceuticals (IONS), Vericel (VCEL) and Voyager Therapeutics (VYGR)

 

BEWARE… How MANY TIMES AM I RIGHT … MORE than MOST!!

The Harvard Apparatus RT (OTC QB HRGN) formerly Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” share pricing works with WHAT news for so long …my treatise is VALIDATED!

  • (4/8) Monday closed up +$0.48 with 4,715 shares traded
  • Friday closed flat with 800 shares traded
  • Thursday closed down -$0.68 with 13,300 shares traded
  • Wednesday closed down -$0.002 with 800 shares traded
  • Tuesday closed $0.00 with 11,900 shares traded
  • (4/1) Monday was up +$0.05 with 1,926 shares traded
  • Friday is a market holiday
  • Thursday closed flat with 150 shares traded
  • Wednesday closed flat with 1,600 shares traded
  • Tuesday closed up +$0.066 with 1,593 shares traded
  • Monday closed down -$0.056 with 1,225 shares traded

Did you notice how it barely trades unless volume is being “pumped.”  This question needs to be answered as HRGN is desperate to finance by any means as past Chinese private placement investors must be feeling … WHAT … TAKEN to the cleaners?

Did you notice how it barely trades unless volume is “pumped” – is it by DST Capital, run by the president of HRGN’s Hong Yu and neighbor, Mrs. Mrs. bin Zhao of Weston, Mass.

  • Will it be funded by Lui Dong Hai, chairman of Dixintong Technology Group (D. Phone, the largest smartphone retailer in China) the husband of Mrs. bin Zhao??

There is more but, isn’t this enough to TOTALLY question the VIABILITARY of Harvard Apparatus GT (OTCQB: HRGN) going onward?

Question, Is it a Ponzi Scheme?

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.